NCT05768932View on ClinicalTrials.gov

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

December 24, 2026

Study Completion Date

December 24, 2026

Conditions
Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric CancerLeukemia Acute Myeloid Leukemia (AML)
Interventions
DRUG

BAL0891

BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)

COMBINATION_PRODUCT

Tislelizumab

Tislelizumab a humanized IgG4 anti-PD-1 monoclonal antibody

COMBINATION_PRODUCT

Paclitaxel

Paclitaxel is a natural product with antitumor activity

Trial Locations (12)

10461

RECRUITING

Montefiore Medical Center, The Bronx

33146

RECRUITING

University of Miami Health System, Coral Gables

75230

WITHDRAWN

Mary Crowley Cancer Research, Dallas

77030

NOT_YET_RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

97239

RECRUITING

OHSU Knight Cancer Institute, Portland

06510

NOT_YET_RECRUITING

Yale New Haven Hospital, New Haven

06591

RECRUITING

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Unknown

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Korean University Anam Hospital, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

SillaJen, Inc.

INDUSTRY